St. Jude Clinical Trials
CPXSMN: CPX-351 in Pediatric Patients with Secondary Myeloid Neoplasms
A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms
Diseases Treated:
Eligibility:
- 1–22 years old
- Treatment-related or secondary MDS/AML
FIX-GT: Factor IX Gene Therapy Study for Patients with Hemophilia B
A Factor IX Gene Therapy Study of a Novel Adeno-associated Viral Vector (FLT180a) in Patients with Hemophilia B
View TrialHAPSAA: Partially Matched Related Donor Bone Marrow Transplant for Patients with Aplastic Anemia
Haploidentical Donor Hematopoietic Cell Transplantation for Patients with Severe Aplastic Anemia
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosis of severe aplastic anemia
- No available matched donor
INSIGHT-HD: Investigating the Genetics of Hematologic Diseases
Diseases Treated:
Non-malignant blood diseases (non-therapeutic)
Eligibility:
- Receiving therapy or a consultation for a non-malignant blood disorder
- Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
LEAPS: Understanding Sickle Cell Disease Transition to Adult Care
Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition
Diseases Treated:
Eligibility:
This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.
- Diagnosis of sickle cell disease (SCD)
- 16 to 20 years old
- English is primary language
LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants
A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Stem Cells
Diseases Treated:
X-linked Severe Combined Immunodeficiency (SCID-X1)
Eligibility:
- Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
- Newborn to 2 years of age
- No prior therapy with allogeneic stem cell transplantation
- No HIV infection
SCDHCT: Reduced Intensity Related Donor HCT for Patients with Severe Sickle Cell Disease
Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 25 years old or younger
- Diagnosed with severe sickle cell disease
- Has a suitable HLA-matched sibling donor or single haplotype matched (half matched) family member donor (parents or siblings)
Collaborative Clinical Trials
BHEEM: Study of BEAM-101 in Patients with Severe Sickle Cell Disease
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 18 to 35 years old
- Diagnosed with severe sickle cell disease
EDO312: Edoxaban, a new Oral Anticoagulant, for Blood Clots in Children
Phase III Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban with Standard Anticoagulant Therapy in Children with Venous Thromboembolism (VTE)
Diseases Treated:
Blood clots (venous thromboembolism)
Eligibility:
This clinical trial is open only to St. Jude patients.
- Newborn to 17 years old (must be younger than 18)
- Diagnosis of blood clot in a vein (venous thromboembolism, also called VTE)
- Requires anticoagulant therapy for at least 90 days
- Received at least 5 days of heparin therapy prior to study
FIX-GT: Factor IX Gene Therapy Study for Patients with Hemophilia B
A Factor IX Gene Therapy Study of a Novel Adeno-associated Viral Vector (FLT180a) in Patients with Hemophilia B
View Trial